Quoin Pharmaceuticals (QNRX) investor relations material

Executive summary

• Special general meeting scheduled for November 12, 2026, to vote on two key proposals regarding beneficial ownership limits and potential adjournment.

• Shareholders of record as of September 23, 2026, are eligible to vote, with each ordinary share and ADS (representing 35 shares) entitled to one vote per share.

• Board recommends voting in favor of both proposals to facilitate future capital raising and ensure flexibility in meeting requirements.

Voting matters and shareholder proposals

• Proposal 1 seeks approval to amend beneficial ownership limits for investors in recent private placements, allowing increases from 4.99% to up to 9.99% upon written notice.

• Proposal 2 allows adjournment of the meeting if more time is needed to solicit votes for Proposal 1.

• Shareholders holding at least 1% of voting rights may submit proposals for general meetings; 5% is required for board nominations or removals.

Board of directors and corporate governance

• Board members and executives participated in the private placements and may benefit from the proposed amendment.

• Board recommends voting "FOR" both proposals and will present resolutions for adoption at the meeting.